Review Article
Advances in radionuclide-labelled nanoprobes for multimodal imaging of tumors
Yue Jianlan, Lin Zhichun
Published 2024-05-25
Cite as Int J Radiat Med Nucl Med, 2024, 48(5): 323-329. DOI: 10.3760/cma.j.cn121381-202305024-00405
Abstract
Early diagnosis and treatment are crucial for improving the cure rate and survival rate of patients with malignant tumors. In recent years, the development of multimodal molecular imaging has provided new directions for the early diagnosis and treatment of malignant tumors. Nuclear medicine imaging has the advantages of high sensitivity, high tissue penetration, and precise quantification, which can play an important role in disease diagnosis and monitoring. Combining it with CT, MRI, optical imaging and other imaging modalities, can provide more comprehensive anatomical and biometabolic information for the diagnosis and treatment of tumors. Currently, the construction of radionuclide-labelled multimodal probes based on nanomedicine strategies has received widespread attention. The authors review the research progress on radionuclide-labelled nanoprobes in multimodal imaging of tumors based on relevant preclinical research results at home and abroad.
Key words:
Radioisotopes; Nanoprobe; Multimodal imaging; Tumor diagnosis
Contributor Information
Yue Jianlan
Department of Nuclear Medicine, Characteristic Medical Center of Chinese People's Armed Police Forces, Tianjin 300162, China
Lin Zhichun
Department of Nuclear Medicine, Characteristic Medical Center of Chinese People's Armed Police Forces, Tianjin 300162, China